Unique cell therapy developed in Houston doses inaugural patient

cancer-fighting innovation

At Rezvani Lab in MD Anderson Cancer Center, scientists train immune cells to fight cancer. Photo via Getty Images

Replay, a genome-writing company headquartered in San Diego, has announced that its first patient has been dosed with an engineered T-Cell Receptor Natural Killer (TCR-NK) cell therapy for relapsed or refractory multiple myeloma.

What does that have to do with Houston? Last year, Replay incorporated a first-in-class engineered TCR-NK cell therapy product company, Syena, using technology developed by Dr. Katy Rezvani at The University of Texas MD Anderson Cancer Center.

Rezvani, a professor of stem cell transplantation and cellular therapy, is the force behind MD Anderson’s Rezvani Lab, a group of 55 people, all focused on harnessing natural killer cells to combat cancer.

“Everybody thinks that the immune system is fighting viruses and infections, but I feel our immune system is capable of recognizing and killing abnormal cells or cells that are becoming cancerous and they're very powerful. This whole field of immunotherapy really refers to the power of the immune system,” Rezvani tells InnovationMap.

Dr. Katy Rezvani is a professor of stem cell transplantation and cellular therapy and the force behind MD Anderson’s Rezvani Lab, which is focused on harnessing natural killer cells to combat cancer. Photo via mdanderson.org

At Rezvani Lab, scientists train immune cells to fight cancer. While cancer drugs like chemotherapy are still the norm, immunotherapy has gained ground, led by Houston research, including the work of Nobel laureate Jim Allison. The harnessed cells are taught to attack cancerous cells, while ignoring healthy ones, says Rezvani. “We’re turning them into heat-seeking missiles,” she explains.

However, there must be a beacon to signal to those “missiles” that there is something to attack. Much of the field has used chimeric antigen receptors (CARs) to achieve that. But they have limitations.

“CARs can only recognize beacons that sit on the surface of the tumor cells,” Rezvani says. “So basically, it's like the tumor cell has to have a hat on it.”

She says that this usually means that the targets that send off a signal are relatively limited, mostly blood cancers. Using T cell receptors (TCRs) may be able to open up the field to look beyond the “hat.” In other words, TCRs can peer inside cells and see what differentiates a tumor cell from healthy cells. With Replay, Rezvani Lab has developed a first-in-class and first-in-human approach of engineering natural killer cells to express the TCR.

There are six different FDA-approved products that use CAR-T cells, but Rezvani says that her TCR-NK-based technology, though still in its early phases, shows great promise.

“We could use it to target many different types of antigens, many different types of cancers, especially solid tumors," she explains. "These cell therapies have a lot of potential — we call them living drugs… It's not like chemotherapy where you have to keep giving different multiple cycles, these cells are very long lived.”

Rezvani, who started her career in London, says that Houston has been instrumental in the success of her lab.

“There are so many opportunities because we have access to some of the most brilliant minds in research,” Rezvani says. “We have some of the best clinicians in the world. We have patients who come to us who are willing to participate in our clinical trials — really put their trust in us — and are committed and want to participate in these clinical studies.”

The role of funding also plays a part. As Rezvani admitted, bringing a new technology to the market is expensive. The philanthropists who help support trials can’t be forgotten among Houston’s finest.

Whether or not Syena produces the first TCR-NK product on the market, Rezvani is enthusiastic and hopeful for the future of her patients.

“The field of immunotherapy is really expanding, the field of cell therapies is expanding, and there is so much promise,” she says. “The promise of AI, big data, all the engineering tools that we have available, the promise of CRISPR — all of that is going to bring what we've learned from biology, from basic science, together to help us make the cell therapies that are going to be safe and and also very effective for our patients.”

From Your Site Articles
A Houston health care company received the green light from the FDA to advance a treatment that's targeting a deadly cancer. Photo via Getty Images

Houston immunotherapy company achieves FDA designation for cancer-fighting vaccine

got the green light

The FDA has granted a Houston-based company a Fast Track designation.

Diakonos Oncology Corp. is a clinical-stage immuno-oncology company that has developed a unique dendritic cell vaccine, DOC1021. The vaccine targets glioblastoma multiforme (GBM), the most common and most lethal malignant brain tumor in adults. The aggressive tumors come with a life expectancy of about 15 months following diagnosis. About 7 percent of those diagnosed survive five years, while the 10-year outlook only sees a one-percent survival rate.

“The FDA’s decision acknowledges the potential of this new treatment approach for a very challenging disease,” Diakonos CEO Mike Wicks says in a press release. “Our protocol represents a first for cancer immunotherapy and could be viable for many types of cancers beyond GBM.”

FDA Fast Track designations are intended to expedite the haste with which drugs with early clinical promise are reviewed, likely taking them to market faster.

DOC1021 uses the body’s natural anti-viral immune response to fight GBM. The vaccine mimics viral infection with the patient’s cancer markers. Essentially, DOC1021 uses the body’s own natural ability to detect and eliminate infected cells.

The technology uses dendritic cells, white blood cells that are able to perceive threats, to its advantage. The unique cancer markers are loaded both internally and externally into the immune cells, just as they would simultaneously occur in a viral infection. The individualized treatment is administered through three precise injections that target deep cervical lymph node chains. By dosing this way, the immune responses are directed straight to the central nervous system.

The results have spoken for themselves: All of the patients who have tried the treatment have exceeded survival expectations. And just as importantly, DOC1021 appears to be extremely safe. No serious adverse effects have been reported.

“Because Phase I clinical trials are generally not statistically powered to demonstrate efficacy, detection of a statistically significant efficacy signal is very promising,” says William Decker, associate professor of immunology at Baylor College of Medicine and inventor of the DOC1021 technology.

The Phase 1 open-label trial of DOC1021 (NCT04552886) is currently taking place at both the University of Texas Health Science Center in Houston and at the MD Anderson Cancer Center at Cooper University Health Care in Camden, NJ. The trial is expected to complete this year.

7 Hills Pharma, an innovative immunotherapy company, was awarded a $13.5 million grant from the Cancer Prevention and Research Institute of Texas. Photo via Getty Images

Houston immunotherapy company to use $13.5M grant to further develop cancer treatments

future of pharma

Between Bangalore and Chennai in the Indian state of Andhra Pradesh, you’ll find the town of Tirupati. It’s home to seven peaks that host a Hindu temple complex devoted to a form of Vishnu, Venkateshvara. It is also the region from which Upendra Marathi originally hails. It’s where his father, and many other family members, attended medical school.

“My father’s first job was to take care of the pilgrims,” recalls Marathi.

It's only natural that his groundbreaking Houston company would be named 7 Hills Pharma.

“That sort of selflessness and giving back, I wanted to embody it in the name of the company,” Marathi says.

Now, 7 Hills Pharma is announcing that last month, it was awarded a $13.5 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). That’s on top of more than $13 million in NIH grants, making the company the second largest recipient of SBIR/STTR grants in Texas.

Launched in 2016, 7 Hills Pharma is working to develop drugs that can overcome the all-too-common problem of immunotherapy resistance. Thanks to the Nobel Prize-winning work of Jim Allison in the realm of immuno-oncology, the field was “very hot” at the time, says Marathi, particularly in Houston.

So what has 7 Hills developed? Oral small molecules that activate integrins — the receptors that allow cells to bind to one another — allowing for the cell-to-cell interactions that create a successful immune response to immune checkpoint inhibitors such as Yervoy. In other words, they have created capsules that increase the effectiveness of drugs that allow the body’s own immune response to fight cancers.

But that’s not all. Tests have shown that the same discovery, called alintegimod, can also augment the effectiveness of vaccines. The pill, which co-founder and co-inventor Peter Vanderslice calls “a beautiful way to amplify the vaccines,” can potentially be applied to anything from influenza to coronavirus.

Their greatest challenge, says Vanderslice, is the very fact that the technology is so novel.

“Most large pharmas are very risk averse,” he explains. “They only want to do ‘me-too’ kinds of drugs.”

7 Hills Pharma is the third company Marathi, both a PhD and an MBA, has helped to found based on technology he co-invented. Vanderslice is director of the molecular cardiology research laboratories at The Texas Heart Institute.

“It’s very much a homegrown company,” Marathi says.

And a small one, at least for now. Working out of JLabs@TMC, the full-time team is currently just Marathi and Siddhartha De, the senior director of development. Marathi convinced De to transplant himself and his family from India for the purpose of assisting 7 Hills with preparing its drugs for clinical readiness.

The CPRIT funds will allow 7 Hills Pharma to hire several long-time team members full-time and with benefits.

“The bringing of talent and bringing of technology to TMC and what was born at Texas Heart Institute is rather remarkable,” says Rob Bent, the company’s director of operations.

The next step for 7 Hills Pharma is a Phase Ib/IIa clinical trial in patients with treatment-resistant solid tumors. And the team just finalized the deck that will help raise another $10 million to $250 million in the company’s series A. And hopefully sooner rather than later, a new set of medical pilgrims will be thanking 7 Hill Pharma for its care.

A UH professor is fighting cancer with a newly created virus that targets the bad cells and leaves the good ones alone. Photo via Getty Images

University of Houston researchers snag $1.8M to develop cancer-fighting virus

immunotherapy innovation

Viruses attack human cells, and that's usually a bad thing — some Houston researchers have received fresh funding to develop and use the evil powers of viruses for good.

The developing cancer treatment is called oncolytic virotherapy and has risen in popularity among immunotherapy research. The viruses can kill cancer cells while being ineffective to surrounding cells and tissue. Basically, the virus targets the bad guys by "activating an antitumor immune response made of immune cells such as natural killer (NK) cells," according to a news release from the University of Houston.

However exciting this rising OV treatment seems, the early stage development is far from perfect. Shaun Zhang, director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston, is hoping his work will help improve OV treatment and make it more effective.

“We have developed a novel strategy that not only can prevent NK cells from clearing the administered oncolytic virus, but also goes one step further by guiding them to attack tumor cells. We took an entirely different approach to create this oncolytic virotherapy by deleting a region of the gene which has been shown to activate the signaling pathway that enables the virus to replicate in normal cells,” Zhang says in the release.

Zhang, who is also a M.D. Anderson professor in the Department of Biology & Biochemistry, has received a $1.8 million grant from the National Institutes of Health to continue his work.

Zhang and his team are specifically creating a new OV — called FusOn-H2 and based on the Herpes simplex 2 virus.

“Our recent studies showed that arming FusOn-H2 with a chimeric NK engager (C-NK-E) that can engage the infiltrated natural killer cells with tumor cells could significantly enhance the effectiveness of this virotherapy,” he says. “Most importantly, we observed that tumor destruction by the joint effect of the direct oncolysis and the engaged NK cells led to a measurable elicitation of neoantigen-specific antitumor immunity.”

Shaun Zhang is the director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston and M.D. Anderson professor in the Department of Biology & Biochemistry. Image via UH.edu

Houston's Nobel Prize winner, Jim Allison, is the star of Breakthrough, which premieres on Independent Lens at 9 pm Monday, April 27, on PBS, PBS.org, and the PBS Video App. Photo via SXSW.com

Documentary featuring Houston Nobel Prize winner to air on PBS

to-watch list

Not all heroes wear capes. In fact, our current coronavirus heroes are donning face masks as they save lives. One local health care hero has a different disease as his enemy, and you'll soon be able to stream his story.

Dr. James "Jim" Allison won the 2018 Nobel Prize in Physiology or Medicine for his work in battling cancer by treating the immune system — rather than the tumor. Allison, who is the chair of Immunology and executive director of the Immunotherapy Platform at MD Anderson Cancer Center, has quietly and often, singularly, waged war with cancer utilizing this unique approach.

The soft-spoken trailblazer is the subject of an award-winning documentary, Jim Allison: Breakthrough, which will air on PBS and its streaming channels on Monday, April 27 at 9 pm (check local listings for channel information). Lauded as "the most cheering film of the year" by the Washington Post, the film follows Allison's personal journey to defeat cancer, inspired and driven by the disease killed his mother.

Breakthrough is narrated by Woody Harrelson and features music by Willie Nelson, adding a distinct hint of Texana. (The film was a star at 2019's South by Southwest film festival.) The documentary charts Alice, Texas native as he enrolls at the University of Texas, Austin and ultimately, cultivates an interest in T cells and the immune system — and begins to frequent Austin's legendary music scene. Fascinated by the immune system's power to protect the body from disease, Allison's research soon focuses on how it can be used to treat cancer.

Viewers will find Allison charming, humble, and entertaining: the venerable doctor is also an accomplished blues harmonica player. Director Bill Haney weaves Allison's personal story with the medical case of Sharon Belvin, a patient diagnosed with melanoma in 2004 who soon enrolled in Allison's clinical trials. Belvin has since been entirely cancer-free, according to press materials.

"We are facing a global health challenge that knows no boundaries or race or religion, and we are all relying on gifted and passionate scientists and healthcare workers to contain and ultimately beat this thing," said Haney, in a statement. "Jim Allison and the unrelenting scientists like him are my heroes – and I'll bet they become yours!"

Jim Allison: Breakthrough premieres on Independent Lens at 9 pm Monday, April 27, on PBS, PBS.org, and the PBS Video App.

------

This article originally ran on CultureMap.

Houston researchers are hard at work in the lab to progress medical advancements at the bedside. Getty Images

These 3 medical innovations are ones to watch in Houston

Research roundup

Every day, important research is being completed under the roofs of Houston medical institutions. From immunotherapy to complex studies on how a memory is made, Houston researchers are discovering and analyzing important aspects of the future of medicine.

Here are three research projects currently being conducted around town.

University of Houston's potential solution to sickle cell disease

Vassiliy Lubchenko is a University of Houston associate professor of chemistry. Courtesy of UH

For the most part, sickle cells have been a mystery to scientists, but one University of Houston professor has recently reported a new finding on how sickle cells are formed — enlightening the medical community with hopes that better understanding the disease may lead to prevention.

Vassiliy Lubchenko, UH associate professor of chemistry, shared his new finding in Nature Communications. He reports that "droplets of liquid, enriched in hemoglobin, form clusters inside some red blood cells when two hemoglobin molecules form a bond — but only briefly, for one thousandth of a second or so," reads a release from UH.

In sickle cell disease, or anemia, red blood cells are crescent shaped and don't flow as easily through narrow blood vessels. The misshapen cells are caused by abnormal hemoglobin molecules that line up into stiff filaments inside red blood cells. Those filaments grow when the protein forms tiny droplets called mesoscopic.

"Though relatively small in number, the mesoscopic clusters pack a punch," says Lubchenko in the release. "They serve as essential nucleation, or growth, centers for things like sickle cell anemia fibers or protein crystals. The sickle cell fibers are the cause of a debilitating and painful disease, while making protein crystals remains to this day the most important tool for structural biologists."

Lubchenko conclusion is that the key to prevent sickle cell disease is to is to stop the formation of the initial clusters so fibers aren't able to grow out of them.

Baylor College of Medicine's immunotherapy research in breast cancer

science-Digital Composite Image Of Male Scientist Experimenting In Laboratory

Baylor College of Medicine researchers are looking into the complexities of immune cells in breast cancer. Getty Images

Baylor College of Medicine researchers are leading an initiative to figure out the potential effect of immunotherapy on different types of breast cancers. Their report is featured in Nature Cell Biology.

The scientists zoned in on two types of immune cells — neutrophils and macrophages — and they found frequency differed in a way that indicated potential roles in immunotherapy.

"Focusing on neutrophils and macrophages, we investigated whether different tumors had the same immune cell composition and whether seemingly similar immune components played the same role in tumor growth. Importantly, we wanted to find out whether differences in immune cell composition contributed to the tumors' responses to immunotherapy," says Dr. Xiang 'Shawn' Zhang, professor at the Lester and Sue Smith Breast Center and member of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, in a news release.

Further exploring the discrepancies between the immune cells and the role they play in tumor growth will help better understand immunotherapy's potential in certain types of breast cancer.

"These findings are just the beginning. They highlight the need to investigate these two cellular types deeper. Under the name 'macrophages' there are many different cellular subtypes and the same stands for neutrophils," Zhang says. "We need to identify at single cell level which subtypes favor and which ones disrupt tumor growth taking also into consideration tumor heterogeneity as both are relevant to therapy."

Rice University, UTHeath, and UH's memory-making study

Researchers from all corners of Houston are diving into how memories are made. Courtesy of Rice University

When you make a memory, your brain cells structurally change. Through a multi-institutional study with researchers from UH, Rice University, and the University of Texas Health Science Center at Houston, we now know more about the way memories are made.

When forming memories, three moving parts work together in the human brain — a binding protein, a structural protein and calcium — to allow for electrical signals to enter neural cells and change the molecular structures in cognition. The scientists compared notes on how on that binding protein works.

The team's study was published in the Proceedings of the National Academy of Sciences. Peter Wolynes, a theoretical physicist at Rice, UH physicist Margaret Cheung, and UTHealth neurobiologist Neal Waxham worked together to understand the complex process memories experience in the process of being made.

"This is one of the most interesting problems in neuroscience: How do short-term chemical changes lead to something long term, like memory?" Waxham says in a release from Rice. "I think one of the most interesting contributions we make is to capture how the system takes changes that happen in milliseconds to seconds and builds something that can outlive the initial signal."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

After trending up all year, Houston VC activity drops in Q3

by the numbers

New data from the PitchBook/NVCA Venture Monitor reveals a seesaw pattern in the Houston area’s venture capital funding.

VC fundraising by Houston-area companies climbed during the first part of this year compared with the same period last year, according to the latest PitchBook/NVCA Venture Monitor. But from 2023 to 2024, the region’s third-quarter VC haul fell by a double-digit percentage.

In the first three quarters of 2024, Houston-area companies collected $1.24 billion in venture capital, the PitchBook/NVCA Venture Monitor shows. That’s up eight percent from the $1.15 billion raised in the first three quarters of 2023.

A look at third-quarter data tells a different story. During the third quarter of 2024, Houston-area companies reaped $529.45 million in VC funding. That’s down 15 percent from $623 million in the third quarter of 2023.

The U.S. saw VC funding rise from $123.5 billion in the first nine months of 2023 to $131.8 billion during the same period in 2024, PitchBook/NVCA data shows. That works out to a 6.7 percent increase. However, Texas experienced a five percent drop — from $5.4 billion in the first nine months of 2023 to $5.13 billion during the same period in 2024.

“While we see some promising signals with lower rates and platform shifts related to AI, we expect the overall VC landscape to [remain] uncertain and strained for the time being,” says Nizar Tarhuni, executive vice president of research and market intelligence at PitchBook.

The new PitchBook/NVCA report forecasts that VC deal value in the U.S. will hit $175.2 billion this year. This figure is shy of annual fundraising totals during the peak of ultra-low interest rates but exceeds the sum for the pandemic year of 2020.

“Venture deal counts seem to have bottomed, but a meaningful market rebound has yet to occur,” says the report.

Houston's Rice University tops new 2025 list of best colleges in Texas

report

The most prestigious higher education institution in Houston has done it again: Rice University has topped WalletHub's 2025 list of the best colleges and universities in Texas for 2025.

The just-released list analyzed more than 800 colleges and universities in the United States using 30 metrics to determine their rankings.

Rice claimed the No. 1 spot in Texas and in WalletHub's regional category of best universities in the South. The school also ranked as the No. 6 best college nationwide.

Rice earned first place in the category for the "best" (or lowest) on-campus crime rates, and ranked 13th for its gender and racial diversity. The school ranked No. 24 in the category for net cost. According to U.S. News and World Report, tuition and fees at Rice cost $60,709 per year. Rice also has an acceptance rate of eight percent, earning the university No. 27 in the category for admission rates.

Here's how WalletHub broke down the rest of Rice's ranking, where No. 1 is the best and No. 49 is the worst:

  • No. 26 – Student-faculty ratio
  • No. 43 – Graduation rate
  • No. 47 – Post-attendance median salary
Rice's recent accolades add to an ongoing winning streak of high rankings. In September, the private university ranked as the No. 1 best Texas college for 2025 by U.S. News, and ranked No. 18 nationally. Education information and review platform Niche also recently ranked Rice the 15th best college in the country and the No. 1 best in Texas for 2025. And Forbes named Rice No. 9 in its 2024-25 list of top U.S. colleges.In the spring, Rice's Jesse H. Jones Graduate School of Business ranked No. 2 in the national publication's ranking of the best graduate schools in Texas.

The only other Houston university to earn a spot in WalletHub's report was the University of Houston, earning No. 12 in Texas and No. 288 nationally.

The top five universities that outranked Rice in the national rankings were Princeton University (No. 1), Yale University (No. 2), Harvard University (No. 3), Massachusetts Institute of Technology (No. 4), and Dartmouth College (No. 5).

The top 10 colleges and universities in Texas are:

  • No. 1 – Rice University
  • No. 2 – The University of Texas at Austin
  • No. 3 – Trinity University
  • No. 4 – Texas A&M University-College Station
  • No. 5 – Southwestern University
  • No. 6 – Texas Christian University
  • No. 7 – Austin College
  • No. 8 – Texas A&M International University
  • No. 9 – University of Dallas
  • No. 10 – Southern Methodist University
The full report can be found on wallethub.com

------

This article originally ran on CultureMap.

Podcast: The 2024 who's who of Houston innovation

houston innovators podcast Episode 257

The Houston Innovation Awards is less than a month away, and the finalists have just been named. In honor of the recent announcement, this week's Houston Innovators Podcast takes a look at the finalists.


But with six years of InnovationMap covering Houston innovation and five years of one-on-one conversations with local entrepreneurs on the Houston Innovators podcast, there's tons to share about most of our honorees. In fact, 23 of our finalists have joined the show before.

Scroll through to listen to conversations with the finalists over the years.

Lori-Lee Elliott of Dauntless XR — finalist in the Female-Founded Business category

Lori-Lee Elliott of Dauntless XR joins the Houston Innovators Podcast to share about her tech company's evolution. Photo via LinkedIn

As Lori-Lee Elliott was building out her company — an augmented reality software company to enhance industrial workflow — she was approached by a representative in the Air Force interested in her technology. That conversation would end up leading to a major rebrand and pivot, as well as multiple federal contracts and grants for the Houston startup.

Dauntless XR — originally founded as Future Sight AR in 2018 — has two software platforms that bring customers flexible mixed reality solutions. The Air Force uses the Aura platform to create 3D replays of missions, while NASA plans to utilize the technology for analyzing space weather data.

"Something that we realized when we built out this platform is that it doesn't have to be for just one thing," Elliott says on the Houston Innovators Podcast. "We can make it ingest all kind of data sources. It does require us as the developers and the architects to go in and learn about each application. And that's great because I get bored easily and it's an endless source of fascination." Read more.

Prabhdeep Singh Sekhon, CEO of Gold H2 — finalist in the Minority-Founded Business and the Deep Tech categories

Prabhdeep Singh Sekhon, CEO of Gold H2, joins the Houston Innovators Podcast. Photo courtesy of Gold H2

Using microbes to sustainably unlock low-cost hydrogen sounds like the work of science fiction, but one Houston company is doing just that.

Gold H2, a spin-off company from Cemvita, has bioengineered subsurface microbes to use in wells to consume carbon and generate clean hydrogen. The technology was piloted two years ago by Cemvita, and now, as its own company with a new CEO, it's safe to say Gold H2's on its way.

"First of all, that was groundbreaking," Prabhdeep Singh Sekhon, CEO of Gold H2, says of the 2022 pilot in the Permian Basin, "to be able to use bugs to produce hydrogen within a couple of days."

"2024 is supposed to be the year where Gold H2 takes off," Sekhon, who joined the company in April, tells the Houston Innovators Podcast. "It was one of those opportunities that I couldn't turn down. I had been following the company. I thought, 'here is this innovative tech that's on the verge of providing a ground-breaking solution to the energy transition — what better time to join the team.'" Read more.

Tatiana Fofanova, co-founder and CEO of Koda Health — finalist in the Female-Founded Business and the Health Tech categories

Tatiana Fofanova, co-founder and CEO of Koda, joined the Houston Innovators Podcast to discuss her company's growth. Image via LinkedIn

It's Tatiana Fofanova's goal to have her company's digital health platform active in all 50 states by the end of the first quarter of 2023. She's already halfway there.

Fofanova founded Koda Health, a B2B Enterprise SaaS solution that guides patients through the process of proactive healthcare planning and document authentication, in early 2020 with her co-founders Dr. Desh Mohan, who serves as chief medical officer, and Katelin Cherry, the company's CTO. The trio connected in the Texas Medical Center's Biodesign Fellowship program and observed how advanced care planning was something that wasn't on the radar for most patients.

The tech platform allows for patients and their providers to get on the same page for their care. Fofanova describes the platform as similar to TurboTax — users answer a series of questions and the program provides a care plan then shared with the patient's doctors. This greatly simplifies — and democratizes — the process for patients and providers both.

"The standard of care for advanced care planning has traditionally been left to patients to do on their own — with estate planning attorney or through a direct-to-consumer solution," Fofanova says on this week's episode of the Houston Innovators Podcast. Read more.

Kelly Pract, CEO and founder of nVenue — finalist in the Female-Founded Business and the AI/Data Science categories

Kelly Pracht joins the Houston Innovators Podcast to discuss how she's expanded nVenue to new sports. Photo courtesy of nVenue

All though career technologist Kelly Pracht began her entrepreneurial journey with her favorite sport, baseball, she's recently expanded the data-backed, fan-engaging sports betting platform to new sports.

Pract, who spent nearly 20 years designing technologies at Hewlett Packard Enterprise, founded nVenue in 2019 after realizing that, while there's endless data and stats available in baseball, there's nothing that exists for fans to engage in that data in real time. So, she set out to build it herself.

At first, the platform launched as a direct-to-fans platform, but Pracht says on the Houston Innovators Podcast that the company pivoted to B-to-B amid its participation in the Comcast SportsTech accelerator.

"The industry was super hungry for fan engagement and sports betting, and we were one of the only companies that could do it," she says on the show. "We found this huge product-market fit of the whole industry wanting ways to engage and bet in real time." Read more.

Sean Kelly, founder and CEO of Amperon — finalist in the Energy Transition Business category

Amperon CEO Sean Kelly joins the Houston Innovators Podcast to share his company's growth and expansion plans. Photo via LinkedIn

The technology that Amperon provides its customers — a comprehensive, AI-backed data analytics platform — is majorly key to the energy industry and the transition of the sector. But CEO Sean Kelly says he doesn't run his business like an energy company.

Kelly explains on the Houston Innovators Podcast that he chooses to run Amperon as a tech company when it comes to hiring and scaling.

"There are a lot of energy companies that do tech — they'll hire a large IT department, they'll outsource a bunch of things, and they'll try to undergo a product themselves because they think it should be IP," he says on the show. "A tech company means that at your core, you're trying to build the best and brightest technology." Read more.

Emma Konet, CTO and co-founder of Tierra Climate — finalist in the Energy Transition Business category

Emma Konet, co-founder and CTO of Tierra Climate, joins the Houston Innovators Podcast. Photo via LinkedIn

If the energy transition is going to be successful, the energy storage space needs to be equipped to support both the increased volume of energy needed and new energies. And Emma Konet and her software company, Tierra Climate, are targeting one part of the equation: the market.

"To me, it's very clear that we need to build a lot of energy storage in order to transition the grid," Konet says on the Houston Innovators Podcast. "The problems that I saw were really on the market side of things." Read more.

Jim Havelka, founder and CEO of InformAI — finalist in the Health Tech category

Jim Havelka, founder and CEO of InformAI, joins the Houston Innovators Podcast to discuss the difference his technology can make on the health care industry. Photo courtesy of InformAI

Hospitals are processing massive amounts of data on a daily basis — but few are optimizing this information in life-saving capacities. A Houston company is seeking to change that.

InformAI has created several tech products to allow hospitals to tap into their data for game-changing health care.

"The convergence of technology, data, and deep learning has really opened up an avenue to look at large volumes of information and look at patterns that can be helpful in patient diagnosis and treatment planning," says CEO Jim Havelka on this week's episode of the Houston Innovators Podcast. Read more.

Matthew Costello, CEO and co-founder of Voyager Portal — finalist in the AI/Data Science category

Matthew Costello, CEO and co-founder of Voyager Portal, joins the Houston Innovators Podcast. Photo courtesy of Voyager

For several years now, Matthew Costello has been navigating the maritime shipping industry looking for problems to solve for customers with his company, Voyager Portal.

Initially, that meant designing a software platform to enhance communications and organization of the many massive and intricate global shipments happening every day. Founded in 2018 by Costello and COO Bret Smart, Voyager Portal became a integral tool for the industry that helps users manage the full lifecycle of their voyages — from planning to delivery.

"The software landscape has changed tremendously in the maritime space. Back in 2018, we were one of a small handful of technology startups in this space," Costello, who serves as CEO of Voyager, says on the Houston Innovators Podcast. "Now that's changed. ... There's really a huge wave of innovation happening in maritime right now." Read more.

Sarah Duggleby, CEO and co-founder of Venus Aerospace — finalist in the Deep Tech Business category

Sarah "Sassie" Duggleby of Venus Aerospace joins the Houston Innovators Podcast this week. Photo courtesy of Venus

Sarah "Sassie" Duggleby is on a mission to get people home in time for dinner — whether they are traveling around the world or working for her business. That's why she founded Venus Aerospace, which is developing hypersonic space planes. It's also why she relocated the company from the West Coast to Houston.

"We knew we had to find a location where we could test our engine and still be home for dinner," Duggleby says on this week's episode of the Houston Innovators Podcast. "Our company vision is 'home for dinner.' We want to fly you across the globe and have you home for dinner. And, if you work for us, we want you home for dinner."

Venus's technology enables this revolutionary travel through its supersonic combustion engine — more akin to a rocket's engine than an airplane's — that allows for travel at a higher elevation, she explains on the show. Read more.


Omair Tariq, founder and CEO of Cart.com — finalist in the Scaleup of the Year category

Omair Tariq of Cart.com joins the Houston Innovators Podcast to share his confidence in Houston as the right place to scale his unicorn. Photo via Cart.com

Last November, Houston-founded logistics tech company Cart.com announced that it would be returning its headquarters to Houston after spending the last two years growing in Austin. But Co-Founder and CEO Omair Tariq says that while the corporate address may have changed, he actually never left.

"I've been in Houston now forever — and I don't think I'm planning on leaving anytime soon. I love Houston — this city has given me everything I have," Tariq says on the Houston Innovators Podcast. "I even love the traffic and everything people hate about Houston."

Tariq, who was born in Pakistan and grew up in Dubai before relocating as a teen to Houston, shared his entrepreneurial journey on the show, which included starting a jewelry business and being an early employee at Blinds.com before it was acquired in 2014 by Home Depot. Read more.

Howard Berman, co-founder and CEO of Coya Therapeutics — finalist in the Scaleup of the Year category

This week's episode of the Houston Innovators Podcast revisits a conversation with Howard Berman, co-founder and CEO of Coya Therapeutics. Photo courtesy of Coya

It's been a busy summer for Houston-based Coya Therapeutics, a clinical-stage biotech company that's creating revolutionary treatments for neurodegenerative diseases like Alzheimer’s, Parkinson’s, and ALS.

In July, Coya announced that has expanded its collaboration with Houston Methodist Research Institute, or HMRI. The publicly traded company also announced fresh funding from the Johnson Center for Cellular Therapeutics.

Last month, Coya reported that it has expanded its treatment research to see how GLP-1 drugs — a trending drug for weight loss — can enhance the effects of its proprietary therapeutics. By combining the medicines, Howard Berman, co-founder and CEO of Coya Therapeutics, says he thinks Coya can better treat these complex immune-based diseases.

Berman joined the Houston Innovators Podcast in April of 2023 to discuss taking Coya public and his passion for the company's mission. Read more.

Carrie Horazeck and Mike Francis of NanoTech Materials — finalist in the Scaleup of the Year category

NanoTech's Chief Commercial Officer Carrie Horazeck and Co-Founder and CEO Mike Francis join the Houston Innovators Podcast to celebrate the nationwide launch of their roof coating product. Photo via LinkedIn

A Houston startup is celebrating its nationwide launch of its flagship product that coats roofs to reduce energy waste.

NanoTech's Nano Shield Cool Roof Coat is a unique product that can be added onto roofs to reduce energy waste on buildings. Co-founder and CEO Mike Francis and Chief Commercial Officer Carrie Horazeck joined the Houston Innovators Podcast to share more details about the product.

"It's just a coating that can go on top of existing structure — any type of commercial roof," Horazeck says on the show. "We have a pretty good amount of data from 2022 showcasing that we can reduce HVAC consumption within the building by about 30 to 40 percent.

"Our clients really see a immediate benefit in their energy bill, and, of course, if you reduce the HVAC consumption, that automatically translates to a decrease in your scope one emissions," she continues. Read more.


Trevor Best, co-founder and CEO of Syzygy Plasmonics — finalist in the Scaleup of the Year category

Trevor Best, CEO of Syzygy Plasmonics, joins the Houston Innovators Podcast. Photo courtesy of Syzygy

When it comes to hardtech, not a lot of startups get the chance to say they're doing things cheaper than they're expected to, but Trevor Best and his clean tech startup, Syzygy Plasmonics, are in the minority there.

"One of the good things about our technology, because we use light instead of heat, we're able to build our reactors out of very low-cost materials — like aluminum and glass. So, we are continually under budget," he says on the Houston Innovators Podcast. "We actually only recently started spending the $23 million we raised over a year ago."

Syzygy, founded in Houston based off research from Rice University, is a chemical company that's developed a photocatalyst-powered hydrogen fuel cell technology that produces a cheaper source of energy that releases fewer carbon emissions. The company has scaled its reactor up in size and hopes the product hits the market next year. The device allows operators of plans power their facilities with a much smaller carbon footprint — at a competitive price, too. Read more.


Sunny Zhang, co-founder of TrueLeap — finalist in the People's Choice: Startup of the Year category

Sunny Zhang joins the Houston Innovators Podcast. Photo via LinkedIn

It's safe to say Sunny Zhang has a handle on the machine and cycle that innovation as a tenured business professor, startup founder, and venture capital investor. An academic at her core, she looks at innovation from the outside in — and inside out — in her various roles.

But there is a throughline for Zhang, and it's observing the innovation cycle. In her 20 years, she's worked closely with startups on the topic.

"My research has always focused on the innovation diffusion process — essentially the psychological and behavioral science of innovation diffusion when a product is introduced in a marketplace. How is that adoption going in a network as a result in many factors — internally and externally in a digital world and in the international and global market," Zhang says on the Houston Innovators Podcast. Read more.

Adrianne Stone, founder of of Bayou City Startups, and finalist in the Ecosystem Builder category

Every month, Adrianne Stone of Bayou City Startups hosts a happy hour for startup founders to create a safe space to network, collaborate, commensurate, and more. Photo courtesy of Adrianne Stone

Starting a company can be daunting and lonely, but entrepreneurs — at least those who call Houston home — have a monthly opportunity to connect with fellow founders thanks to Adrianne Stone.

Stone, who's had a varied career from getting her PhD in Translational Biology & Molecular Medicine at Baylor College of Medicine and joining the 23andMe team as a scientist to supporting founders at Capital Factory, launched Bayou City Startups last year to help connect Houston founders over beers. Now, Stone shares on the Houston Innovators Podcast that her monthly Bayou City Startups meetups attract over 50 attendees on average.

"Being the venture associate with Capital Factory in Houston, I'd seen what the Houston ecosystem had to offer. There were events — happy hours, coffee meet-ups, all these things," Stone says. "But it was not just a casual networking event usually. I wanted a consistent community where I could show up and say, 'guys, I had the worst week,' to people who got where I was coming from and who could commensurate or lean in and help." Read more.

Carlos Estrada, head of Venture Acceleration at BioWell, and finalist in the Ecosystem Builder category

Carlos Estrada, head of Venture Acceleration at BioWell, joins the Houston Innovators Podcast to share why Houston is already a great hub for bioindustrial innovation. Photo courtesy of BioWell

Bioindustrial technologies have a high potential for impacting sustainability — but they tend to need a little bit more help navigating the startup valley of death. That's where the BioWell comes in.

Carlos Estrada, head of Venture Acceleration at BioWell, says the idea for the accelerator was came to First Bight Ventures, a Houston-based biomanufacturing investment firm, as it began building its portfolio of promising companies.

"While we were looking at various companies, we found ourselves finding different needs that these startups have," Estrada says on the Houston Innovators Podcast. "That's how the opportunity for the BioWell came about." Read more.

Juliana Garaizar, founding partner of Energy Tech Nexus, and finalist in the Ecosystem Builder category

Juliana Garaizar joins the Houston Innovators Podcast. Photo courtesy of Juliana Garaizar

As Juliana Garaizar, former head of the Houston incubator and vice president of innovation for Greentown, says on this week's Houston Innovators Podcast, the surprising element emerging in Houston is the need for an entry point into the United States from foreign companies — mostly emerging from Latin America.

"We're realizing that we're becoming the landing pad for many international companies or companies coming from other ecosystems," she says on the show. "We are glad to be that landing pad for many companies looking to enter the United States through Texas."

Atul Varadhachary of Fannin Innovation Studio, and finalist in the Ecosystem Builder category

Atul Varadhachary of Fannin joins the Houston Innovators Podcast. Photo via LinkedIn

Commercializing a life science innovation that has the potential to enhance or even save the lives of millions of patients is a marathon, not a sprint. That's how Atul Varadhachary thinks of it, and he's leading an organization that's actively running that race for several different early-stage innovations.

For over a decade, Fannin has worked diligently to develop promising life science innovations — that start as just an idea or research subject — by garnering grant funding and using its team of expert product developers to build out the technology or treatment. The model is different from what you'd see at an accelerator or incubator, and it also varies from the path taken by an academic or research institution. Read more.

Phillip Yates, founder and CEO of Equiliberty Inc., and finalist in the Ecosystem Builder category

Phillip Yates joins the Houston Innovators Podcast to discuss two initiatives he's launching to support diverse founders in Houston. Photo courtesy of Equiliberty

Phillip Yates is juggling a lot. The Houston lawyer started Equiliberty, a technology company that's part financial resource and part social network, to help diverse communities create lasting wealth. Now, he's also launching Diversity Fund Houston — a $3 million initiative to support diverse tech founders — ahead of the inaugural Black Entrepreneurship Week, which Yates is hosting in Houston starting Saturday, November 27.

While it is a handful, all three initiatives align with Yates's goal to move the needle on improving equity when it comes to access to capital, finding a community, and creating institutional change. Just like most Black professional, he's faced his share of challenges — but he's persevered thanks to his mentors, family, and supportive network.

"Everytime I failed, there was somebody there that made sure I stayed on track," Yates shares on the Houston Innovators Podcast.

Now Yates, across his efforts, wants to help create this same type of support for others. Equaliberty connects users to a hyper-local network and mentor, as well as relationships to financial institutions and key resources. Read more.


Carrie Colbert, founding and general partner of Curate Capital, and finalist in the Investor of the Year category

Carrie Colbert saw an opportunity is funding female-founded companies, and she's taking it. Photo courtesy of Curate Capital

Carrie Colbert wasn't planning on becoming a venture capital investor — it just happened organically.

"This has been kind of a backwards process. Our fund was driven by demand," Colbert, founder and general partner of Houston-based Curate Capital, says on this week's episode of the Houston Innovators Podcast. "We were getting such good deal flow in terms of quantity and quality."

Colbert says she originally carved out a practical career and worked her way up the corporate ladder within the energy industry — first at Anadarko Petroleum and then at Hilcorp Energy Co. — for almost 20 years. On the side, she was also establishing herself as a prominent content creator specializing in all things colorful on her blog and Instagram.

It was through the network she created that she started learning about up-and-coming businesses that she wanted to get involved in — first as an angel investor for a few years and now through her VC. Read more.

Chris Howard, CEO of Softeq, and finalist in the Investor of the Year category

On this week's episode of the Houston Innovators Podcast, Softeq Founder and CEO Chris Howard shares how he's focusing on supporting the Houston innovation ecosystem. Photo courtesy of Softeq

When Chris Howard founded his technology consulting firm in 1997, there wasn't a tech scene in town. But as the company grew over the past 20-plus years, so did Houston's innovation ecosystem — and Howard had a front-row seat for it all.

Now, Softeq's CEO is making sure he's doing what he can to further support tech startups in Houston with the recently launched Softeq Innovation Lab.

"I want to give back as an entrepreneur and a Houstonian," Howard says on this week's episode of the Houston Innovators Podcast. "I really want to leverage Softeq's expertise in order to help these companies grow in the same way that we've been doing for a couple of decades now." Read more.

Samantha Lewis, partner at Mercury Fund, and finalist in the Investor of the Year category

The future of Web3, investing in Houston, and how founders need to be prepared for 2023 — Samantha Lewis of Mercury joins the Houston Innovators Podcast. Photo courtesy of Mercury

Heading into the new year, startup founders in Houston and beyond need to focus on conserving and raising cash, says Samantha Lewis, partner of Houston-based venture capital firm Mercury.

“We all know it’s turbulent market times. We’re unsure where the market is going, and when there’s uncertainty in the public markets, that puts uncertainty in the private markets,” Lewis says on this week's episode of the Houston Innovators Podcast. “What I’ve been spending the past two quarters doing is working with our portfolio companies to just make sure our balance sheets are bulked up for what’s to come in 2023.”

She says Mercury's startup portfolio has focused on extending each company's runway financially through 2024 — and she recommends all startups to try to do the same. She advises on the show that even if a company raised funding within the past year, open on the same terms and valuation just to bridge the gap.Read more.


Mitra Miller, vice president of Houston Angel Network, and finalist in the Mentor of the Year category

Mitra Miller, vice president and board member of the Houston Angel Network, joins the Houston Innovators Podcast to share her passion for growing angel investors in Houston. Photo via LinkedIn

One of the biggest components of a well-functioning startup ecosystem is inarguably access to capital, and Mitra Miller is dedicated to enhancing education around investment and growing Houston's investor base.

As vice president and board member of the Houston Angel Network, the oldest angel network in Texas and one of the most active angel networks in the country, Miller strives to provide guidance to new and emerging angel investors as well as founders seeking to raise money from them.

"Most founders have no idea or understanding of how investors think — we are not an ATM," Miller says on the Houston Innovators Podcast. "We are really partners you are getting married to for the next 5, 8, 10 years — sometimes longer. We need to bring your allies in every sense of the word." Read more.

View All Listings